IgG4-Related Disease

Xencor Inc (NASDAQ: XNCR) is on a roll this week, having announced Q4 2015 earnings beats Monday and initiating Phase II trials for its XmAb®5871 on two patients, one with IgG4-Related Disease and another with Systemic Lupus Erythematosus. The stock saw significant movement upward in...